1 July 2005 in Antimicrobial Agents and Chemotherapy
The intraerythrocytic development of Plasmodium falciparum correlates with increasing levels of the polyamines putrescine, spermidine, and spermine in the infected red blood cells; and compartmental analyses revealed that the majority is associated with the parasite. Since depletion of cellular polyamines is a promising strategy for inhibition of parasite proliferation, new inhibitors of polyamine biosynthesis were tested for their antimalarial activities. The ornithine decarboxylase (ODC) inhibitor 3-aminooxy-1-aminopropane (APA) and its derivatives CGP 52622A and CGP 54169A as well as the S -adenosylmethionine decarboxlyase (AdoMetDC) inhibitors CGP 40215A and CGP 48664A potently affected the bifunctional P. falciparum ODC-AdoMetDC, with
K
i
values in the low nanomolar and low micromolar ranges, respectively. Furthermore, the agents were examined for their in vitro plasmodicidal activities in 48-h incubation assays. APA, CGP 52622A, CGP 54169A, and CGP 40215A were the most effective, with 50% inhibitory concentrations below 3 μM. While the effects of the ODC inhibitors were completely abolished by the addition of putrescine, growth inhibition by the AdoMetDC inhibitor CGP 40215A could not be antagonized by putrescine or spermidine. Moreover, CGP 40215A did not affect the cellular polyamine levels, indicating a mechanism of action against P. falciparum independent of polyamine synthesis. In contrast, the ODC inhibitors led to decreased cellular putrescine and spermidine levels in P. falciparum , supporting the fact that they exert their antimalarial activities by inhibition of the bifunctional ODC-AdoMetDC.
8 February 2017 in PLOS Pathogens
Resistance against all available antimalarial drugs calls for novel compounds that hit unexploited targets in the parasite. Here, we show that the recently discovered Plasmodium falciparum lactate/proton symporter, PfFNT, is a valid druggable target, and describe a new class of fluoroalkyl vinylogous acids that potently block PfFNT and kill cultured parasites. The original compound, MMV007839, is derived from the malaria box collection of potent antimalarials with unknown targets and contains a unique internal prodrug principle that reversibly switches between a lipophilic transport form and a polar, substrate-analogous active form. Resistance selection of cultured P. falciparum parasites with sub-lethal concentrations of MMV007839 produced a single nucleotide exchange in the PfFNT gene; this, and functional characterization of the resulting PfFNT G107S validated PfFNT as a novel antimalarial target. From quantitative structure function relations we established the compound binding mode and the pharmacophore. The pharmacophore largely circumvents the resistance mutation and provides the basis for a medicinal chemistry program that targets lactate and proton transport as a new mode of antimalarial action. The fight against malaria, i.e. one of the three major infectious diseases and transmitted by mosquitos, is conducted at three levels: i. transmission control (by attacking the mosquito vector or biological processes of vector infection), ii. vaccination (by stimulating the immune system to produce antibodies against molecular parasite surface structures), and iii. antimalarial drugs (by developing and applying small molecules that interfere with vital biochemical pathways). Despite strong efforts on levels i. and ii., small molecule drugs remain an indispensible antimalarial means; however, emergence and spreading of resistant malaria parasites against all currently used drugs pose a growing threat to treatment success. Therefore, novel drug targets need to be identified and exploited. Here, we show that a recently discovered lactic acid transporter, PfFNT, is a novel valid drug target and we provide first compounds that potently block transport and kill malaria parasites. Lactic acid is the metabolic end product of the parasites’ energy generation metabolism and interfering with this biochemical pathway represents a new mode of action against malaria parasites.
2 April 2007 in Australian Journal of Chemistry
A-Phenylethyl substituted bis(pivaloyloxymethyl) ester analogues of the natural products Fosmidomycin and FR900098 have been synthesized, and their in vitro antimalarial activity determined. The a-phenylethyl substituted Fosmidomycin analogue displays moderate in vitro antimalarial activity against the chloroquine-sensitive strain 3D7 of Plasmodium falciparum.